01
Precedent Match
Every funding decision tells a story. A²I™ maps the patterns across 158 PTAC decisions to show which funding evidence claims have historically determined access — and which have not.
Explore corpus →Ascentra · A²I™ Platform
Get medicine to those who need it most
Data intelligence to inform equitable and fair access
Three capabilities. One disciplined funding narrative.
Move from corpus exploration to risk rehearsal — with equity signals embedded at every step.
02
Funding Evidence Claim Risk
Not all evidence carries equal weight. A²I™ identifies which claims in your evidence base PTAC has challenged in similar submissions — ranked by how load-bearing each claim is to the funding outcome.
View risk scores →03
Remediation Map
For every high-risk funding evidence claim, A²I™ surfaces what evidence has historically closed the gap — so the right evidence reaches the right patients.
Equity landscape →What makes a funding evidence claim high risk
Three signal types drive the majority of PTAC challenges. Each has a distinct remediation pathway.
Absent Evidence
No direct, prospective evidence exists for the funded population. The submission relies on extrapolation from adjacent populations, surrogate outcomes, or non-randomised data — PTAC's most common basis for a Not Recommended or Deferred decision.
Indirectness Mismatch
Trial endpoints do not map to the clinical outcomes PHARMAC needs to fund — e.g., PFS instead of OS, or biomarker response instead of quality of life. High risk when the submission asks PTAC to accept a surrogate as clinically meaningful.
Equity Evidence Gap
Evidence specifically addressing outcomes for Māori, Pacific, or high-deprivation populations is absent. Under PHARMAC's Te Tiriti obligations, this gap can block funded access or generate binding conditions — even when the overall efficacy evidence is acceptable.
Therapy area intelligence
Explore PTAC decisions, Access Risk Scores, and equity signals by therapy area.
O
Oncology
Solid tumours, haematological malignancies, targeted therapies
View →R
Rare Disease
Genetic conditions, ultra-orphan indications, gene therapies
View →I
Immunology
Autoimmune, inflammatory, biologic therapies
View →N
Neurology
MS, Parkinson's, epilepsy, migraine, dementia
View →D
Diabetes
Type 2 diabetes, GLP-1 agents, SGLT-2 inhibitors
View →Re
Respiratory
Asthma, COPD, pulmonary hypertension
View →M
Mental Health
Depression, treatment-resistant conditions
View →C
Cardiovascular
Heart failure, stroke prevention, dyslipidaemia
View →Query 158 PTAC decisions in one place
Filter by drug, indication, recommendation, domain, and equity flag — with A²I™ funding evidence claim enrichment on every row.